Literature DB >> 23429735

Molecular pathogenesis and mechanisms of thyroid cancer.

Mingzhao Xing1.   

Abstract

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in understanding its molecular pathogenesis in recent years, as best exemplified by the elucidation of the fundamental role of several major signalling pathways and related molecular derangements. Central to these mechanisms are the genetic and epigenetic alterations in these pathways, such as mutation, gene copy-number gain and aberrant gene methylation. Many of these molecular alterations represent novel diagnostic and prognostic molecular markers and therapeutic targets for thyroid cancer, which provide unprecedented opportunities for further research and clinical development of novel treatment strategies for this cancer.

Entities:  

Mesh:

Year:  2013        PMID: 23429735      PMCID: PMC3791171          DOI: 10.1038/nrc3431

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  208 in total

1.  Discovery of common variants associated with low TSH levels and thyroid cancer risk.

Authors:  Julius Gudmundsson; Patrick Sulem; Daniel F Gudbjartsson; Jon G Jonasson; Gisli Masson; Huiling He; Aslaug Jonasdottir; Asgeir Sigurdsson; Simon N Stacey; Hrefna Johannsdottir; Hafdis Th Helgadottir; Wei Li; Rebecca Nagy; Matthew D Ringel; Richard T Kloos; Marieke C H de Visser; Theo S Plantinga; Martin den Heijer; Esperanza Aguillo; Angeles Panadero; Enrique Prats; Almudena Garcia-Castaño; Ana De Juan; Fernando Rivera; G Bragi Walters; Hjordis Bjarnason; Laufey Tryggvadottir; Gudmundur I Eyjolfsson; Unnur S Bjornsdottir; Hilma Holm; Isleifur Olafsson; Kristleifur Kristjansson; Hoskuldur Kristvinsson; Olafur T Magnusson; Gudmar Thorleifsson; Jeffrey R Gulcher; Augustine Kong; Lambertus A L M Kiemeney; Thorvaldur Jonsson; Hannes Hjartarson; Jose I Mayordomo; Romana T Netea-Maier; Albert de la Chapelle; Jon Hrafnkelsson; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2012-01-22       Impact factor: 38.330

2.  The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).

Authors:  Joanna Xing; Ruixin Liu; Mingzhao Xing; Barry Trink
Journal:  Biochem Biophys Res Commun       Date:  2010-12-23       Impact factor: 3.575

3.  Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.

Authors:  Dingxie Liu; Mingzhao Xing
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

4.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

5.  MTOR downregulates iodide uptake in thyrocytes.

Authors:  Elaine Cristina Lima de Souza; Alvaro Souto Padrón; William Miranda Oliveira Braga; Bruno Moulin de Andrade; Mário Vaisman; Luiz Eurico Nasciutti; Andrea Claudia Freitas Ferreira; Denise Pires de Carvalho
Journal:  J Endocrinol       Date:  2010-04-14       Impact factor: 4.286

6.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.

Authors:  P L Dahia; D J Marsh; Z Zheng; J Zedenius; P Komminoth; T Frisk; G Wallin; R Parsons; M Longy; C Larsson; C Eng
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

7.  Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

Authors:  Paolo Salerno; Valentina De Falco; Anna Tamburrino; Tito Claudio Nappi; Giancarlo Vecchio; Rebecca E Schweppe; Gideon Bollag; Massimo Santoro; Giuliana Salvatore
Journal:  J Clin Endocrinol Metab       Date:  2009-10-30       Impact factor: 5.958

8.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

Authors:  R Donghi; A Longoni; S Pilotti; P Michieli; G Della Porta; M A Pierotti
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 9.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

10.  High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.

Authors:  Gisele Oler; Janete M Cerutti
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

View more
  506 in total

1.  Usefulness of NRAS codon 61 mutation analysis and core needle biopsy for the diagnosis of thyroid nodules previously diagnosed as atypia of undetermined significance.

Authors:  Eun Kyung Jang; Won Gu Kim; Eui Young Kim; Hyemi Kwon; Yun Mi Choi; Min Ji Jeon; Jung Hwan Baek; Jeong Hyun Lee; Tae Yong Kim; Young Kee Shong; Jene Choi; Dong Eun Song; Won Bae Kim
Journal:  Endocrine       Date:  2015-11-07       Impact factor: 3.633

2.  Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.

Authors:  Jie Ming; Zeming Liu; Wen Zeng; Yusufu Maimaiti; Yawen Guo; Xiu Nie; Chen Chen; Xiangwang Zhao; Lan Shi; Chunping Liu; Tao Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Princess D Rodriguez; Lauren Cozzens; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Cancer Res       Date:  2020-06-17       Impact factor: 5.852

4.  Cystathione β-Synthase Is Increased in Thyroid Malignancies.

Authors:  Elba A Turbat-Herrera; Matthew J Kilpatrick; Jie Chen; Andrew T Meram; James Cotelingam; Ghali Ghali; Christopher G Kevil; Domenico Coppola; Rodney E Shackelford
Journal:  Anticancer Res       Date:  2018-11       Impact factor: 2.480

5.  Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.

Authors:  Shaohua Zhan; Jinming Li; Tianxiao Wang; Wei Ge
Journal:  Oncologist       Date:  2018-05-08

6.  Local anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway.

Authors:  Yuan-Ching Chang; Yi-Chiung Hsu; Chien-Liang Liu; Shih-Yuan Huang; Meng-Chun Hu; Shih-Ping Cheng
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

Review 7.  The Role and Importance of Molecular Tests in Approach to Thyroid Nodules.

Authors:  Levent Gürbüzler
Journal:  Turk Arch Otorhinolaryngol       Date:  2016-04-06

8.  MiR-574-5p mediates the cell cycle and apoptosis in thyroid cancer cells via Wnt/β-catenin signaling by repressing the expression of Quaking proteins.

Authors:  Zhejia Zhang; Xinying Li; Qian Xiao; Zhiming Wang
Journal:  Oncol Lett       Date:  2018-02-15       Impact factor: 2.967

9.  Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Authors:  Soeren Latteyer; Vera Tiedje; Katharina König; Saskia Ting; Lukas C Heukamp; Lydia Meder; Kurt Werner Schmid; Dagmar Führer; Lars Christian Moeller
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

10.  BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.

Authors:  Fei Wang; Shihua Zhao; Xiaopei Shen; Guangwu Zhu; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Mingzhao Xing
Journal:  J Clin Oncol       Date:  2018-08-02       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.